# US 10,117,929 B1 · Nucleic acid-based adjuvant and porcine vaccine composition including the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,929 B1
- Document ID: US10117929B1
- Status: Granted
- Kind: B1
- Application number: 15/821,774
- Filed: 2017-11-23
- Granted: 2018-11-06
- Earliest claimed: 2017-11-23
- Assignees: National Pingtung University of Science and Technology
- Applicants: National Pingtung University Of Science And Technology
- Inventors: Hso-Chi Chaung; Guan-Ming Ke; Mei-Li Wu
- Web page: https://patentgrep.com/patent/US10117929B1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 39/12: Viral antigens
- A61K 39/215: Coronaviridae, e.g. avian infectious bronchitis virus
- A61P 31/14: for RNA viruses
- C07H 21/04: with deoxyribosyl as saccharide radical
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/575: {humoral response}
- C12N 2710/16721: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/16734: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/16762: by genetic engineering
- C12N 2710/16771: Demonstrated in vivo effect
- C12N 2770/20021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20062: by genetic engineering
- C12N 2770/20071: Demonstrated in vivo effect
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a nucleic acid-based adjuvant and a porcine vaccine composition including the same. The nucleic acid-based adjuvant, which is a nucleic acid fragment consisting of a sequence listing as SEQ ID NO: 1, can be used as the nucleic acid-based adjuvant of a vaccine composition, thereby elevating the protective ability of the porcine vaccine composition.

## Claims

### Claim 1

A porcine vaccine composition, comprising:
an antigen, comprising an inactivated virus strain, wherein the inactivated virus strain comprises gE gene-knockout pseudorabies (PR) virus strain or chemically inactivated porcine epidemic diarrhea (PED) virus strain; and
a nucleic acid-based adjuvant consisting of a nucleic acid fragment having a sequence listing as SEQ ID NO: 1.